Description
Treat chronic hepatitis, hepatic coma, neurasthenia, epilepsy, gastric acid deficiency and other diseases; long-term use can improve the intelligence of children with neurological defects and reduce the effects of ammonia poisoning in the blood.
Details
Specification
| L-Glutamic Acid | CP2020 | EP11 | USP43 |
| Assay | ≥98.5% | 98.5-100.5% | 98.5-100.5% |
| PH | / | / | / |
| Specific rotation[a]D20 | +31.5°-+32.5° | +30.5°-+32.5° | +31.5°-+32.5° |
| Specific rotation[a]D25 | / | / | / |
| Transmittance(T430) | ≥98.0% | / | / |
| Appearance of solution | / | clear & colorless | / |
| Chloride(Cl) | ≤0.02% | ≤0.02% | ≤0.02% |
| Ammonium(NH4) | ≤0.02% | ≤0.02% | / |
| Sulfate(SO4) | ≤0.02% | ≤0.03% | ≤0.02% |
| Iron(Fe) | ≤5PPM | ≤10PPM | ≤10PPM |
| Heavy metals(Pb) | ≤10PPM | / | ≤15PPM |
| Arsenic | ≤1PPM | / | / |
| Other amino acids | ≤0.50% | / | Individual impurities≤0.5% |
| Total impurities≤2.0% | |||
| Ninhydrin-positive substances | / | conform | / |
| Loss on drying | ≤0.50% | ≤0.50% | ≤0.10% |
| Residue on ignition | ≤0.10% | ≤0.10% | ≤0.10% |
| Total plate count | / | ≤ 1000 CFU/g | / |
| Moulds & Yeasts | / | ≤ 100 CFU/g | / |
